Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

49.23 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
The Metabolic Split: Why Eli Lilly Soars as Novo Stumbles ↗
Via MarketBeat
News headline image
Can Pfizer Crash the Lilly and Novo Nordisk Weight-Loss Party? ↗
Eli Lilly and Novo Nordisk may want to enjoy their duopoly while they can. 
Via The Motley Fool
News headline image
Why Eli Lilly Stock Soared Today ↗
The healthcare giant gained nearly $100 billion in market value. 
Via The Motley Fool
News headline image
Novo Nordisk To Launch Ozempic Pills Following Flat Growth In Diabetes Segment In 2025 ↗
The Ozempic pill will be launched in Q2 2026 and be available in doses 1.5 mg, 4 mg, and 9 mg. 
Via Stocktwits
News headline image
Novo Nordisk Plunges After Releasing a Brutal Forecast. Should You Dump the Stock? ↗
The pharmaceutical giant expects sales to decline this year, potentially by double-digit percentages. 
Via The Motley Fool
VKTX Shares Garner Retail Attention Ahead Of Q4 Earnings Report ↗
Via Stocktwits
Novo Nordisk In Green After Oral Wegovy Clocks Over 18K Prescriptions In A Week ↗
Via Stocktwits
News headline image
Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026 ↗
Eli Lilly is riding the GLP-1 gravy train, while this competitor is struggling to get on board. 
Via The Motley Fool
News headline image
Novo Awaits FDA Call On Higher-Dose Wegovy In Early 2026 – NVO Stock Extends Decline Pre-Market On Weak Guidance ↗
Novo Nordisk submitted a supplemental New Drug Application (NDA) to the FDA in November, and under the CNPV program, a review decision is usually expected within one to two months after the filing is... 
Via Stocktwits
Topics Intellectual Property
News headline image
Novo Nordisk Vs Eli Lilly: Which Big Pharma Stock Has More Upside This Year Amid Earnings Season? ↗
Novo leads early in oral obesity drugs, while Lilly counters with a strong injectable franchise and an oral pill nearing approval. 
Via Stocktwits
Topics Intellectual Property
News headline image
Stock Market Today, Feb. 3: Novo Nordisk Slides as Pricing Pressure Clouds Obesity-Drug Outlook ↗
Novo Nordisk dropped after management forecasts weaker 2026 growth, shifting attention from recent results to pricing pressure and rising competition in obesity treatments. 
Via The Motley Fool
Topics Initial Public Offering Intellectual Property Stocks
News headline image
What Drove US Indices Down Today? ↗
Investors dumped technology stocks as they move to safer assets like Gold and Silver that rose today. 
Via Stocktwits
Topics Artificial Intelligence ETFs Stocks
News headline image
Novo Nordisk Shares Tumble On Q4 Miss, Weak Sales Forecast And Competition Concerns ↗
The drugmaker now expects fiscal 2026 adjusted sales down 5% to 13%. 
Via Stocktwits
News headline image
The Pharma Reckoning: 2026 Earnings Unveil a New Era of 'TrumpRx' Deals and Looming Patent Cliffs
As the pharmaceutical industry enters the heart of its Q4 2025 earnings season this February 2, 2026, a clear divide has emerged between the high-flying giants of the metabolic gold rush and those... 
Via MarketMinute
Topics Economy Government Intellectual Property
News headline image
Is Novo Nordisk Stock a Bargain Right Now? ↗
Novo Nordisk just introduced a GLP-1 pill, but the company makes more than just weight-loss drugs. 
Via The Motley Fool
News headline image
Should You Buy Novo Nordisk Stock on Oral Wegovy's Strong Launch? ↗
This could finally be the start of the drugmaker's comeback. 
Via The Motley Fool
News headline image
Eli Lilly CEO Sees Medicare Coverage Support Upcoming Obesity Pill Launch: Report ↗
CEO Dave Ricks said in an interview with CNBC that many patients are currently paying in cash for the oral obesity drug from rival Novo Nordisk. 
Via Stocktwits
Topics Government
News headline image
Demand for Novo Nordisk's Weight Loss Pill Is Strong Out of the Gate. Is the Stock Due for a Big Rally? ↗
Novo Nordisk's weight loss pill could give the company's numbers a big boost this year. 
Via The Motley Fool
News headline image
FDA Decision on Eli Lilly's Weight Loss Pill Delayed to Q2. Is This Bad News for the Stock? ↗
The target action date for orforglipron is now April 10. 
Via The Motley Fool
News headline image
2 Beaten-Down Growth Stocks Ready to Bounce Back ↗
Both companies are trading at attractive valuations today. 
Via The Motley Fool
News headline image
1 Biotech Stock Set to Rebound in 2026 ↗
The Wegovy maker is coming off a dismal showing in 2025, but it's a legitimate 2026 rebound candidate. 
Via The Motley Fool
News headline image
1 Pharmaceutical Stock Set to Rebound in 2026 ↗
Novo Nordisk stock will ride a wave of demand for Ozempic pills in 2026. 
Via The Motley Fool
News headline image
2 Pharmaceutical Stocks Set to Rebound in 2026 ↗
There might be massive upside ahead for these drugmakers. 
Via The Motley Fool
News headline image
Where Will Eli Lilly Be in 10 Years? ↗
Eli Lilly is the leader in GLP-1 weight loss drugs today, but that advantage won't last forever. 
Via The Motley Fool
Topics ETFs Intellectual Property
News headline image
Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker? ↗
Both companies may succeed in this industry. 
Via The Motley Fool
News headline image
Prediction: This Healthcare Stock Could Soar by 40% in 2026 ↗
This pharmaceutical giant has recently caught fire, and the stock's run is likely just beginning. 
Via The Motley Fool
News headline image
3 Growth Stocks to Invest $1,000 in Right Now ↗
It comes as no surprise that all three of them are capitalizing on relatively new, but game-changing, developments. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Should You Dump Eli Lilly's Shares After This Setback? ↗
The company got some bad news to start 2026. 
Via The Motley Fool
News headline image
Viking Therapeutics (VKTX) 2026 Deep Dive: Challenging the Obesity Duopoly
Date: January 23, 2026 Introduction In the high-stakes arena of metabolic medicine, few companies have generated as much speculative fervor and clinical awe as Viking Therapeutics (NASDAQ: VKTX). As of... 
Via Finterra
Topics Intellectual Property
News headline image
Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026 ↗
This biotech has candidates in late-stage clinical development. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.